Health TrialsbyHealthPanel

Survival Outcomes of Lung Cancer

ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHunan Province Tumor Hospital

About this trial

This is a prospective study to analyze the survival outcomes of different groups about lung cancer patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Understand the requirements and contents of the clinical trial .

Age ≥ 18 years.

Histopathology or cytology confirmed lung cancer

ECOG <=2.

Disqualifiers

Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity. Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose.

Ongoing (or inability to discontinue) possibly potent CYP1A2, CYP3A inhibitor (1 week), or inducer (2 weeks) drug therapy or herbal supplements within 1-2 weeks prior to the first dose.

Presence of spinal cord compression or meningeal metastasis.

History of other malignant tumors within 2 years.

Trial population

lung cancer

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Treatment

    Drug

    Treatment decisions guided by molecular profiling and clinical judgment of principal investigators

Treatment groups

20,000 Participants
are divided into 5 treatment groups
Group A: Cohorts 11 intervention
Group B: Cohorts 21 intervention
Group C: Cohorts 31 intervention
Group D: Cohorts 41 intervention
Group E: Cohorts 51 intervention

Trial outcomes

Primary outcomes

1

Progression-free survival (PFS)

PFS defines as first dose to first documented disease progression assessed by investigator or death due to any cause.

Time frame
Time from first subject dose to study completion, or up to 5 years

Secondary outcomes

1

Overall survival (OS)

To assess overall response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as the proportion of subjects who have a complete response (CR) or a partial response (PR)

Time frame
Time from first subject dose to study completion, or up to 5 years
2

Adverse events (AEs)

Number of participants with adverse events (AEs) according to CTCAE 5.0

Time frame
Time from first subject dose to study completion, or up to 5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Hunan Province Tumor Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now